Trogenix
13 known investors
Find your way into Trogenix
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system. Its lead program, TGX-007, is a gene therapy for glioblastoma in a Phase I/II clinical trial, with potential applications in solid tumours and regenerative medicine.
Investors · 13
.jpeg){kind=logo}
Also in the syndicate · 8
Funding
SEC filings, press & company announcements$95M disclosed across 1 round · 2025
- $95MSeries AOct 2025 · 4 sources
IQ Capital (lead), 4BIO Capital, Brain Tumor Investment Fund, Brain Tumour Investment Fund, Calculus Capital, Cancer Research Horizons, Capital, Eli Lilly, Eli Lilly and Company, LongeVC, Meltwind, National Brain Tumor Society
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Trogenix do?
- Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system. Its lead program, TGX-007, is a gene therapy for glioblastoma in a Phase I/II clinical trial, with potential applications in solid tumours and regenerative medicine.
- Who are Trogenix's investors?
- Trogenix's investors include AIN Ventures, IQ Capital, 4BIO Capital, Calculus Capital Ltd., LongeVC.
- How much funding has Trogenix raised?
- Trogenix has disclosed $95M raised across 1 round.